Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibitor development in previously untreated patients with severe haemophilia A: a nationwide multicentre study in Finland.

Haemophilia : the official journal of the World Federation of Hemophilia - 1 Sept 2016

Vepsäläinen K, Lassila R, Arola M, Huttunen P, Koskinen S, Ljung R, Lähteenmäki P, Möttönen M, Riikonen P

Abstract excerpt

INTRODUCTION: Currently the most serious treatment complication of haemophilia is the inhibitor development (ID), i.e. neutralizing antibody development. AIM: This nationwide multicentre study in Finland evaluated the incidence and risk factors of ID in previously untreated patients (PUPs) with severe haemophilia A (FVIII:C < 0.01 IU mL(-1) ). METHODS: We enrolled all PUPs (N = 62) born between June 1994 and May...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing
Share to Coagulants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Factor VIII

Share to Finland

Share to Hemophilia A

Share to Hemorrhage

Share to Proportional Hazards Models

Share to Severity of Illness Index

Source

Identifiers

PMID: 27339837
DOI: 10.1111/hae.12974

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibitor development in previously untreated patients with severe haemophilia A: a nationwide multicentre study in Finland.PMID 27339837Read ↗

Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010.Semantic proximity Read ↗

Risk factors for high-titer inhibitor development in children with hemophilia A: results of a cohort study.Semantic proximity Read ↗

Treatment related factors and inhibitor development in children with severe haemophilia A.Semantic proximity Read ↗

Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet studySemantic proximity Read ↗

Inhibitors in the Swedish population with severe haemophilia A and B: a 20-year survey.Semantic proximity Read ↗

Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future?Semantic proximity Read ↗

Improved prediction of inhibitor development in previously untreated patients with severe haemophilia A.Semantic proximity Read ↗

Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products.Semantic proximity Read ↗

Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis.Semantic proximity Read ↗

Prospective observational cohort studies for studying rare diseases: the European PedNet Haemophilia Registry.Semantic proximity Read ↗

Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors.Semantic proximity Read ↗

The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.